• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Shigella Infections (Shigellosis) - Pipeline Review, H2 2012 Product Image

Shigella Infections (Shigellosis) - Pipeline Review, H2 2012

  • ID: 2335420
  • November 2012
  • 41 pages
  • Global Markets Direct

Shigella Infections (Shigellosis) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Shigella Infections (Shigellosis) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Shigella Infections (Shigellosis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Shigella Infections (Shigellosis). Shigella Infections (Shigellosis) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Shigella Infections (Shigellosis).
- A review READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Shigella Infections (Shigellosis) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Shigella Infections (Shigellosis) 7
Shigella Infections (Shigellosis) Therapeutics under Development by Companies 9
Shigella Infections (Shigellosis) Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Shigella Infections (Shigellosis) Therapeutics – Products under Development by Companies 14
Shigella Infections (Shigellosis) Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Shigella Infections (Shigellosis) Therapeutics Development 16
GlycoVaxyn AG 16
Variation Biotechnologies, Inc. 17
Shigella Infections (Shigellosis) – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
GVXN-SD133 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
WRSS-1 Vaccine - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Invaplex 50 Vaccine - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
SC-599 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
WRSs2 + WRSs3 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Oral Shigella Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Inactivated whole cell shigella flexneri 2a vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Shigella Vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Shigella Infections (Shigellosis) Therapeutics – Drug Profile Updates 33
Shigella Infections (Shigellosis) Therapeutics – Discontinued Products 34
Shigella Infections (Shigellosis) – Product Development Milestones 35
Featured News & Press Releases 35
Oct 24, 2011: Thallion Pharmaceuticals Announces Presentation Of Blinded Results From Low Dose Cohort Of Phase II SHIGATEC Trial At IDSA Annual Meeting 35
Oct 11, 2011: Thallion Resumes Patient Recruitment In Phase II SHIGATEC Trial 35
Sep 13, 2011: Thallion Provides Update On Phase II SHIGATEC Trial 36
Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease 37
Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine 38
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41

List of Tables
Number of Products Under Development for Shigella Infections (Shigellosis), H2 2012 7
Products under Development for Shigella Infections (Shigellosis) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
GlycoVaxyn AG, H2 2012 16
Variation Biotechnologies, Inc., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Shigella Infections (Shigellosis) Therapeutics – Drug Profile Updates 33
Shigella Infections (Shigellosis) Therapeutics – Discontinued Products 34

List of Figures
Number of Products under Development for Shigella Infections (Shigellosis), H2 2012 7
Products under Development for Shigella Infections (Shigellosis) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos